Table 3.
Baseline descriptive statistics
| Control (N = 36) |
Intervention (N = 33) |
Total (N = 69) |
|
|---|---|---|---|
| Gender | |||
| Female | 22 (61.1%) | 25 (75.8%) | 47 (68.1%) |
| Male | 14 (38.9%) | 8 (24.2%) | 22 (31.9%) |
| Age | |||
| Median (Q1, Q3) | 82.5 (77.5, 88.0) | 86.0 (83.0, 88.0) | 85.0 (79.0, 88.0) |
| FAST | |||
| Missing | 1 | 1 | 2 |
| 4 | 1 (2.9%) | 2 (6.2%) | 3 (4.5%) |
| 5 | 1 (2.9%) | 2 (6.2%) | 3 (4.5%) |
| 6 | 24 (68.6%) | 25 (78.1%) | 49 (73.1%) |
| 7 | 9 (25.7%) | 3 (9.4%) | 12 (17.9%) |
| Charlson | |||
| Median (Q1, Q3) | 1.0 (1.0, 2.0) | 2.0 (1.0, 2.0) | 1.0 (1.0, 2.0) |
| MMSE | |||
| Missing | 6 | 3 | 9 |
| Median (Q1, Q3) | 3.0 (1.0, 6.8) | 6.0 (2.0, 10.0) | 4.0 (1.0, 9.2) |
| No. of psychotropic drugs | |||
| Mean (range) | 2.91 (1–6) | 2.78 (0–5) | 2.85 (0–6) |
| SDI | |||
| Median (Q1, Q3) | 3.0 (0.0, 18.0) | 3.0 (0.0, 12.5) | 3.0 (0.0, 17.5) |
| WASO | |||
| Median (Q1, Q3) | 73.9 (34.8, 106.6) | 56.5 (32.9, 85.2) | 62.7 (32.9, 95.0) |
Q1 25th percentile, Q3 75th percentile, FAST Functional Assessment Staging Test, Charlson Charlson Comorbidity Index, MMSE Mini-Mental State Exam, SDI Sleep Disorder Inventory, WASO Wake After Sleep Onset